Manages central diabetes insipidus. ANDA 77414, held by Apotex. Desmopressin Acetate.
As of Nov 16, 2026, ANDA 77414 (Desmopressin Acetate), held by Apotex, was first approved by FDA on Mar 7, 2006, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Central Diabetes Insipidus Desmopressin acetate tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin acetate is ineffective for the treatment of nephrogenic diabetes insipidus. Patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. Continued response to desmopressin acetate can be monitored by measuring urine volume and osmolality.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 7, 2006 | Original application | Approved | None posted |
| Desmopressin Acetate0.1MG · tablet;oral | Desmopressin Acetate | Rx |
| Desmopressin Acetate0.2MG · tablet;oral | Desmopressin Acetate | Rx |
| Jan 23, 2015 | Supplement 8Labeling | Approved | |
| Sep 3, 2008 | Supplement 5Labeling | Approved | None posted |
| Mar 7, 2006 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters